Загрузка...
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
INTRODUCTION: Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)(1–40) and Aβ(1–42) in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This...
Сохранить в:
| Опубликовано в: : | Alzheimers Dement (N Y) |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6258891/ https://ncbi.nlm.nih.gov/pubmed/30511011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.10.001 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|